Literature DB >> 17261118

Using EQ-5D to derive general population-based utilities for the quality of life assessment of growth hormone deficiency in adults (QoL-AGHDA).

Maria Kołtowska-Häggström1, Björn Jonsson, Dag Isacson, Kerstin Bingefors.   

Abstract

OBJECTIVE: Disease-oriented quality of life (QoL) measures that are not preference-based lack legitimacy for direct use in cost-utility analyses. This has prompted the search for other methods for deriving utilities. The QoL Assessment of Growth Hormone Deficiency in Adults questionnaire (QoL-AGHDA) is a disease-oriented measure used to assess impairment in QoL in adults with growth hormone deficiency. The present study was designed to generate a model for deriving utilities from the QoL-AGHDA.
METHODS: The EQ-5D, the QoL-AGHDA, and demographic questions were mailed to a random sample (n = 3005) of the Swedish population (response rate 65%). Multiple regression analysis was used to obtain cross-validated parameters of QoL-AGHDA-based utilities. Two models were developed (simple and full versions). The simple version used the EQ-5D(index) (derived from European values) as the dependent variable, and age, sex, and QoL-AGHDA score as independent variables in a regression analysis. The full model utilized all available demographic information. The QoL-AGHDA scores were thus transformed into a single score (0-1), corresponding to the QoL-AGHDA-based utility.
RESULTS: The simple transformation algorithm was U (QoL-AGHDA-based utilities) = 1.05 - 0.0189 x QoL-AGHDA score - 0.00238 x age - 0.0127 x sex (male = 0; female = 1). The mean of the weighted estimate for the population (n = 1752) was 0.85 (SD 0.10). The estimate for men (n = 861; mean 0.86; SD 0.10) was higher (P < 0.001) than for women (n = 891; mean 0.84; SD 0.10).
CONCLUSION: For practical reasons, the simple model can be recommended for deriving utilities directly from the QoL-AGHDA for the Swedish population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17261118     DOI: 10.1111/j.1524-4733.2006.00146.x

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  11 in total

Review 1.  Evaluation of content on EQ-5D as compared to disease-specific utility measures.

Authors:  Fang-Ju Lin; Louise Longworth; A Simon Pickard
Journal:  Qual Life Res       Date:  2012-06-23       Impact factor: 4.147

2.  Predicting EQ-5D utility scores from the 25-item National Eye Institute Vision Function Questionnaire (NEI-VFQ 25) in patients with age-related macular degeneration.

Authors:  Nalin Payakachat; Kent H Summers; Andreas M Pleil; Matthew M Murawski; Joseph Thomas; Kristofer Jennings; James G Anderson
Journal:  Qual Life Res       Date:  2009-06-19       Impact factor: 4.147

3.  Utility estimation in chronic obstructive pulmonary disease: a preference for change?

Authors:  Jennifer Petrillo; Floortje van Nooten; Paul Jones; Maureen Rutten-van Mölken
Journal:  Pharmacoeconomics       Date:  2011-11       Impact factor: 4.981

4.  Health related quality of life among Rheumatic Fever and Rheumatic Heart Disease patients in India.

Authors:  Jyoti Dixit; Gaurav Jyani; Shankar Prinja; Yashpaul Sharma
Journal:  PLoS One       Date:  2021-10-29       Impact factor: 3.240

5.  Health-related quality of life, and its determinants, among older people in rural Vietnam.

Authors:  Le V Hoi; Nguyen Tk Chuc; Lars Lindholm
Journal:  BMC Public Health       Date:  2010-09-11       Impact factor: 3.295

6.  Deriving reference values and utilities for the QoL-AGHDA in adult GHD.

Authors:  J J V Busschbach; B H R Wolffenbuttel; L Annemans; W J Meerding; M Kołtowska-Häggström
Journal:  Eur J Health Econ       Date:  2010-04-17

7.  The cost-effectiveness of growth hormone replacement therapy (Genotropin®) in hypopituitary adults in Sweden.

Authors:  Kristian Bolin; Rickard Sandin; Maria Koltowska-Häggström; Jane Loftus; Christin Prütz; Björn Jonsson
Journal:  Cost Eff Resour Alloc       Date:  2013-09-30

8.  Growth hormone (GH) replacement in hypopituitary adults with GH deficiency evaluated by a utility-weighted quality of life index: a precursor to cost-utility analysis.

Authors:  Maria Kołtowska-Häggström; Paul Kind; John P Monson; Björn Jonsson
Journal:  Clin Endocrinol (Oxf)       Date:  2007-09-04       Impact factor: 3.478

9.  Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D.

Authors:  Paulos Teckle; Helen McTaggart-Cowan; Kim Van der Hoek; Stephen Chia; Barb Melosky; Karen Gelmon; Stuart Peacock
Journal:  Health Qual Life Outcomes       Date:  2013-12-01       Impact factor: 3.186

10.  Peer support for patients with type 2 diabetes in rural communities of China: protocol for a cluster randomized controlled trial.

Authors:  Bo Xie; Xiu-li Ye; Zi-lin Sun; Min Jia; Hui Jin; Chang-ping Ju; Li Yao; Carvalho Husni Da Costa De Vladmir; Yanxiaoxiao Yang
Journal:  BMC Public Health       Date:  2014-07-23       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.